Published in

Microbiology Society, Journal of General Virology, 3(89), p. 653-659, 2008

DOI: 10.1099/vir.0.83386-0

Links

Tools

Export citation

Search in Google Scholar

Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein

Journal article published in 2008 by Ania M. Owsianka, Alexander W. Tarr ORCID, Zhen-Yong Keck, Ta-Kai Li, Jeroen Witteveldt, Richard Adair, Steven K. H. Foung ORCID, Jonathan K. Ball, Arvind H. Patel
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

The humoral response to hepatitis C virus (HCV) may contribute to controlling infection. We previously isolated human monoclonal antibodies to conformational epitopes on the HCV E2 glycoprotein. Here, we report on their ability to inhibit infection by retroviral pseudoparticles incorporating a panel of full-length E1E2 clones representing the full spectrum of genotypes 1–6. We identified one antibody, CBH-5, that was capable of neutralizing every genotype tested. It also potently inhibited chimeric cell culture-infectious HCV, which had genotype 2b envelope proteins in a genotype 2a (JFH-1) background. Analysis using a panel of alanine-substitution mutants of HCV E2 revealed that the epitope of CBH-5 includes amino acid residues that are required for binding of E2 to CD81, a cellular receptor essential for virus entry. This suggests that CBH-5 inhibits HCV infection by competing directly with CD81 for a binding site on E2.